Dihydromyricetin (DHM or DMY) is a flavonoid derived from natural sources with a range of confirmed biological benefits. It exhibits anti-inflammatory, antioxidant, anti-tumor, and anti-viral activities. DHM is recognized for its high biosafety, making it a promising subject for further research. This article offers a comprehensive overview of DHM’s pharmacological properties, mechanisms, and recent research developments in the cardiovascular, urinary, digestive, nervous, and respiratory systems. The review summar…

Deformable batteries with compressive and impact-buffered abilities are essential for enhancing battery safety. However, existing compressible electrodes often face limited physical deformation and generate high stress, leading to package bulges of batteries. Here, we present a metamaterial-inspired design to develop negative Poisson's ratio (NPR) structural electrodes using a directional freezing 3D printing-assisted strategy. This approach incorporates both macroscopic NPR structures and microscopic directional …

Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy, with or without angiogenesis inhibitors, have been investigated as the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, it remains unclear which treatment modalities are the most effective and safest, as comparative studies evaluating these treatment options are limited. Objectives: This article aims to compare the relative efficacy and safety of ICIs + Chemo + angiogenesis inhibitors versus ICIs + Chemo …

The moiré superlattice in twisted van der Waals heterostructures is of central importance for the modulation of the electronic and optical properties of the system, yet the mechanical dissipation of such moiré systems remains largely unexplored. Here, we report the experimental observations of energy dissipation across both vertical and lateral directions along the moiré superstructures, revealing a significant increase in dissipation at moiré ridges compared to flat domains. Comparison of the measurements with a …

Abstract Background Mirikizumab (MIRI), an anti-IL-23p19 antibody, demonstrated robust efficacy in improving clinical and endoscopic endpoints with an acceptable safety profile1. In patients with moderate-to-severely active Crohn’s disease (CD), we explored the trajectory of response to MIRI or ustekinumab (USTE), an anti-IL-23p19p40 active comparator. Methods MIRI (N=572) and USTE (N=285) patients described previously1 were assessed via Growth Mixture Model to identify distinct clusters based on individual patien…